10-Q: Xilio Therapeutics Secures Capital, Extends Runway

Xilio Therapeutics reported increased collaboration revenue and a significant capital raise, extending its cash runway through Q3 2026, despite ongoing operating losses and substantial doubt about its ability to continue as a going concern.

Summary

• Xilio Therapeutics, a clinical-stage biotechnology company, reported a net loss of $15.8 million for the three months ended June 30, 2025, compared to $13.9 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $29.1 million, an improvement from $31.1 million for the six months ended June 30, 2024.
• Collaboration and license revenue significantly increased to $8.1 million for the three months ended June 30, 2025, up from $2.4 million in the prior year, primarily due to the new agreement with AbbVie.
• Cash and cash equivalents stood at $121.6 million as of June 30, 2025, compared to $55.3 million at December 31, 2024.
• The company anticipates its existing cash and cash equivalents will fund operations through the end of the third quarter of 2026.
• A follow-on public offering in June 2025 generated initial gross proceeds of $50.0 million, with potential for up to an additional $100.0 million from warrant exercises by the second half of 2026.
• The company continues to advance its clinical-stage product candidates, vilastobart (in Phase 2 with Roche) and XTX301 (in Phase 1 with Gilead), and preclinical programs like XTX501.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company faces significant financial challenges, including ongoing losses and a going concern warning, the substantial capital raise and increased collaboration revenue provide a critical lifeline and extend the cash runway. Progress in clinical trials and new partnerships are positive indicators, but the inherent risks of early-stage biotech development and the Nasdaq compliance issue temper the overall outlook.

Positives

• Collaboration and license revenue increased significantly to $8.1 million for the three months ended June 30, 2025, up from $2.4 million in the prior year, driven by the AbbVie agreement.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $14.5 million, an increase from $9.5 million in the prior year, largely due to deferred revenue from collaborations.
• The June 2025 follow-on public offering raised initial gross proceeds of $50.0 million, significantly boosting cash reserves.
• Potential for up to an additional $100.0 million in gross proceeds from the cash exercise of Series B and Series C warrants by the second half of 2026.
• The company's cash and cash equivalents of $121.6 million are projected to fund operating expenses and capital expenditure requirements through the end of the third quarter of 2026.
• Progress in clinical development for vilastobart, with updated Phase 2 data presented in May 2025 showing additional anti-tumor activity and a well-tolerated safety profile.
• Continued enrollment in Phase 1B monotherapy dose expansion for XTX301 under the exclusive license agreement with Gilead.

Negatives

• The company reported an accumulated deficit of $412.9 million as of June 30, 2025, and continues to incur significant operating losses.
• Net loss for the three months ended June 30, 2025, worsened to $15.8 million from $13.9 million in the same period of 2024.
• The company's recurring losses from operations raise substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq deficiency letter on April 4, 2025, for failing to meet the minimum $1.00 bid price requirement, with a deadline of October 1, 2025, to regain compliance.
• Research and development expenses increased by $4.1 million for the three months ended June 30, 2025, compared to the prior year, driven by increased clinical development activities for vilastobart and manufacturing for XTX501.
• General and administrative expenses increased by $1.3 million for the three months ended June 30, 2025, primarily due to higher personnel-related costs and professional fees.

Risks

• Recurring losses from operations raise substantial doubt regarding the ability to continue as a going concern, necessitating additional capital raises.
• Failure to regain compliance with Nasdaq's continued listing requirements could lead to delisting, negatively impacting stock price and access to capital markets.
• Business is highly dependent on the success of early-stage product candidates, which require significant additional preclinical and clinical development before regulatory approval and commercial launch.
• The company's technological approach to tumor-activated product candidates is unproven, and there is no assurance of developing commercially valuable products.
• Preclinical development is uncertain, and programs may experience delays or never advance to clinical trials.
• Substantial delays, termination, or suspension of clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• Product candidates may cause undesirable or unexpectedly severe side effects, potentially delaying or preventing regulatory approval or limiting commercial profile.
• Interim and preliminary clinical trial data may change as more patient data become available and are subject to audit and verification.
• Development of product candidates in combination with third-party drugs means limited or no control over the safety, supply, or regulatory status of those drugs.
• Manufacturing biologics is complex, and problems could lead to delays in development or commercialization programs.
• Reliance on third-party contract development and manufacturing organizations (CDMOs) poses risks, including regulatory compliance, limited capacity, and supply interruptions.
• Reliance on third parties to conduct, supervise, and monitor IND-enabling studies and clinical trials, with unsatisfactory performance potentially harming the business.
• Collaborations, licenses, or similar arrangements with third parties may not be successful, limiting the market potential of product candidates.
• Significant reliance on WuXi Biologics in China for research, development, and manufacturing activities exposes the company to geopolitical and trade-related risks, including potential U.S. government restrictions.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, potentially leading to others developing or commercializing products more successfully.
• Inability to obtain and maintain patent protection for product candidates or proprietary technologies, or insufficient scope of protection, could allow competitors to develop similar products.
• Reliance on in-license agreements for patent rights carries risks, including loss of rights due to non-compliance or inability to acquire necessary future intellectual property.
• The regulatory approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying commercialization.
• Potential exposure to costly and damaging liability claims from testing product candidates in the clinic or following commercial sale.
• Unstable global economic and political conditions, including heightened inflation and geopolitical conflicts, could adversely affect business, financial condition, stock price, and ability to raise capital.

Future Outlook

The company anticipates its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements through the end of the third quarter of 2026. However, it expects operating losses and negative operating cash flows to continue for the foreseeable future as it advances its pipeline. The company will need to raise substantial additional capital through warrant exercises, milestone payments from existing collaborations, or new equity offerings, debt financings, or partnerships to fund future operations and alleviate substantial doubt about its ability to continue as a going concern.

Management Comments

• We are leveraging our proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment.
• To date, we have presented data across our clinical-stage programs showing clinical validation for our tumor-activation platform.
• We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our programs and product candidates into and through development, seek marketing approvals, and maintain our public company infrastructure.
• Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates, if approved.

Industry Context

The immuno-oncology (I-O) therapy market for cancer treatment is highly competitive, with numerous pharmaceutical and biotechnology companies developing novel approaches. Xilio Therapeutics aims to differentiate itself by focusing on tumor-activated, or 'masked,' I-O therapies designed to reduce systemic toxicity, a common limitation of current I-O treatments. The industry is characterized by significant R&D investment, long development timelines, and high regulatory hurdles. Recent legislative changes like the Inflation Reduction Act (IRA) and ongoing discussions around drug pricing and trade policies (e.g., U.S.-China tensions impacting CDMOs like WuXi Biologics) introduce additional complexities and financial pressures for biotech companies.

Comparison to Industry Standards

• The company's approach of developing tumor-activated I-O therapies, such as vilastobart (anti-CTLA-4) and XTX301 (IL-12), aims to address the systemic toxicity issues prevalent in traditional I-O treatments like Bristol Myers Squibb's Yervoy (ipilimumab) and AstraZeneca's Imjudo (tremelimumab), which are approved anti-CTLA-4 therapies.
• While there are no approved IL-12 therapies for cancer, XTX301 competes with other modified IL-12 delivery programs in development from companies like Cullinan Management Inc. and Dragonfly Therapeutics, Inc.
• For XTX501, a masked PD-1/IL-2 bispecific, the company faces competition from other bispecific PD-1 targeted IL-2 antibodies in development by companies such as Regeneron Pharmaceuticals, Inc. and Roche.
• In the masked T cell engager space, Xilio's programs targeting PSMA, CLDN18.2, and STEAP1 compete with other masked T cell engager programs from companies like Janux Therapeutics, Inc. (PSMA) and Werewolf Therapeutics, Inc. (STEAP1), as well as non-masked T cell engager programs from Amgen Inc. and Zai Lab Limited (CLDN18.2 and STEAP1).
• The company's financial position, characterized by recurring losses and a going concern warning, is common for clinical-stage biotechnology companies that have not yet commercialized products, as they require substantial capital for long-term R&D and clinical trials. The recent capital raise and collaborations are critical for extending its operational runway, a common strategy in the industry to mitigate liquidity risks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is exposed to potential product liability risks inherent in the research, development, manufacturing, marketing, and use of biopharmaceutical products, which could lead to lawsuits.
• The company may be subject to claims of intellectual property infringement or violations by third parties, which could result in costly litigation, substantial damages, or injunctions preventing development or commercialization.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• The company may be subject to claims that it or its employees have wrongfully used or disclosed confidential information of competitors or are in breach of non-competition or non-solicitation agreements.

Related Party Transactions

• In February 2025, the company entered into a stock purchase agreement with AbbVie Inc., a related party, pursuant to which the company issued and sold 4,347,826 shares of its common stock to AbbVie Inc. for an aggregate purchase price of $10.0 million.
• In March 2024, the company entered into a stock purchase agreement with Gilead Sciences, Inc., a related party, under which Gilead purchased $25.0 million of the company's common stock and prefunded warrants in three private placements.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the recent follow-on offering and future warrant exercises, as well as from any future capital raises. The Nasdaq delisting risk could negatively impact share price and liquidity. The exculpation of officers limits avenues for seeking damages.
• **Employees**: The March 2024 restructuring included a 21% workforce reduction, impacting employees. The company's ability to attract and retain qualified personnel is critical for future success.
• **Customers/Patients**: Continued development of tumor-activated I-O therapies aims to significantly improve outcomes for cancer patients by reducing systemic side effects. Delays in development or failure to obtain regulatory approval would impact patient access to potential new treatments.
• **Suppliers/CDMOs**: Reliance on third-party CDMOs, particularly WuXi Biologics in China, exposes the company to supply chain disruptions and geopolitical risks, which could affect the availability of materials for product development.
• **Creditors**: The 'going concern' warning indicates increased risk for creditors, although the recent capital raise provides a temporary improvement in liquidity.

Next Steps

• Anticipate reporting additional data from the Phase 2 clinical trial for vilastobart in the first half of 2026.
• Continue enrollment of patients in Phase 1B monotherapy dose expansion for XTX301.
• Advance preclinical programs for XTX501 and masked T cell engager molecules into IND-enabling activities.
• Monitor the closing bid price of common stock and consider options to regain compliance with Nasdaq's minimum bid price requirement by October 1, 2025.
• Seek additional capital through potential warrant exercises, milestone payments from collaborations, or new financing arrangements to fund operations beyond Q3 2026.

Key Dates

Recommendation

Xilio Therapeutics presents a mixed financial picture. While the recent capital raise of $50.0 million and potential for an additional $100.0 million from warrant exercises significantly bolster its cash position and extend its runway through Q3 2026, the company explicitly acknowledges 'substantial doubt about its ability to continue as a going concern' due to recurring operating losses. The Nasdaq minimum bid price deficiency adds another layer of risk. However, the increased collaboration revenue from new partnerships with AbbVie and ongoing work with Gilead and Roche demonstrate continued external validation of its tumor-activated immuno-oncology platform and pipeline. For a seasoned investor, the high-risk, high-reward nature of clinical-stage biotechnology is evident. The recent financing provides necessary liquidity to continue advancing its promising, albeit early-stage, product candidates. Given the significant uncertainties (clinical trial success, regulatory approval, future capital needs, Nasdaq compliance) balanced by the recent financial lifeline and strategic collaborations, a 'hold' recommendation is appropriate. It suggests maintaining current positions to observe further clinical and financial developments without adding new capital due to the inherent risks.

Keywords

Biotechnology, Immuno-oncology, Cancer therapy, Clinical-stage, SEC filing, 10-Q, Xilio Therapeutics, XLO, Oncology, Drug development, Tumor-activated, Antibody, IL-12, CTLA-4, Bispecific, T cell engager, Capital raise, Warrants, Collaboration, Gilead, AbbVie, Roche, Nasdaq listing